CAR-T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives.
Cell Biochem Funct
; 42(2): e3955, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38379220
ABSTRACT
Heart diseases remain the primary cause of human mortality in the world. Although conventional therapeutic opportunities fail to halt or recover cardiac fibrosis, the promising clinical results and therapeutic efficacy of engineered chimeric antigen receptor (CAR) T cell therapy show several advancements. However, the current models of CAR-T cells need further improvement since the T cells are associated with the triggering of excessive inflammatory cytokines that directly affect cardiac functions. Thus, the current study highlights the critical function of heart immune cells in tissue fibrosis and repair. The study also confirms CAR-T cell as an emerging therapeutic for treating cardiac fibrosis, explores the current roadblocks to CAR-T cell therapy, and considers future outlooks for research development.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos Quiméricos
Limite:
Humans
Idioma:
En
Revista:
Cell Biochem Funct
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China